Overview

The 90% Effective Sedation Dose Of Midazolam

Status:
Unknown status
Trial end date:
2019-12-15
Target enrollment:
0
Participant gender:
All
Summary
There are no clear conclusive clinical reports defining the adequate effective dose of midazolam in patients undergoing day-case esophageal-gastro-duodenoscopy (EGD). Defining such dosage will facilitate practitioners who are not anesthesia professionals to administer sedative drugs to establish a satisfactory level of moderate sedation. Our first aim is to determine the effective dose for 90% of patients (ED 90) of midazolam undergoing day-case EGD.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
King Fahad Specialist Hospital Dammam
Treatments:
Midazolam
Criteria
Inclusion Criteria:

- ASA 1&2

Exclusion Criteria:

1. Patients with hypersensitivity to midazolam,

2. Age less than 18,

3. Obstructive sleep apnea

4. known or suspected memory impairment,

5. Patients with psychiatric disorders,

6. visual or hearing impairment and pregnancy